-+ 0.00%
-+ 0.00%
-+ 0.00%
ST Huluwa (605199.SH) subsidiary obtained simethicone emulsion drug registration certificate
Share
Listen to the news

Zhitong Finance App News, ST Huluwa (605199.SH) issued an announcement. Guangxi Weiwei Pharmaceutical Co., Ltd. (“Guangxi Weiwei”), a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for simethicone emulsion approved and issued by the State Drug Administration.

The indications for simethicone emulsion are: 1. It is used to treat symptoms of discomfort caused by excessive gas accumulation in the gastrointestinal tract: such as bloating, etc., and can also be used after surgery. 2. It can be used as an adjuvant for abdominal imaging tests (e.g. X-rays, ultrasound, gastroscopy) and as an additive in contrast suspensions. The drugs approved this time were reviewed and approved according to technical requirements consistent with the quality and efficacy of the reference formulation. After approval, they are treated as if they have passed the consistent evaluation of the quality and efficacy of generic drugs.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending